📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI, Ya

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI, Yale, and MSK Launch Open-Source Digital Pathology Consortium

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus AI, 𝐘𝐚𝐥𝐞 𝐍𝐞𝐰 𝐇𝐚𝐯𝐞𝐧 and 𝐌𝐒𝐊 launch the IMS Consortium.

➤ Initiative aims to accelerate 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 standardization and adoption.

➤ Tempus will open source the 𝐏𝐚𝐢𝐠𝐞 𝐈𝐌𝐒 platform and key modules.

➤ Platform includes slide viewing, case management, and 𝐀𝐈 𝐨𝐫𝐜𝐡𝐞𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 tools.

➤ Consortium seeks to build an open, interoperable digital pathology ecosystem.

➤ Focus includes AI-powered diagnostics, biomarker discovery, and workflow efficiency.

➤ Additional academic and industry members are expected to join over time.

💬 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

“Pathology is entering a transformative new era,” said Razik Yousfi, SVP and GM of AI Products at Tempus.

“Advances in deep learning and AI foundation models are enabling digital pathology to generate powerful insights directly from whole slide images, from cancer detection to molecular profiling. As demand for diagnostic and biomarker testing continues to rise, digital pathology offers a unique opportunity to enhance patient care by optimizing tissue utilization, uncovering actionable biomarkers, and improving laboratory workflows. We are excited to collaborate with YNHH and MSK to help bring the full potential of digital pathology into clinical practice.”

“Digital pathology is transforming how we deliver diagnostics, advance translational research, and integrate AI into clinical care,” said Chen Liu, MD, PhD, Chief of Pathology at YNHH.

“We are excited to join the Tempus IMS Consortium as a founding member and collaborate with leading academic and industry partners to help build an open, scalable, and interoperable digital pathology ecosystem. Open innovation and shared standards will be essential to accelerating adoption, improving workflow efficiency, and enhancing patient care.”

"Digital pathology lacks opensource and openaccess clinical-grade solutions for on-prem/cloud slide viewing, case management, and AI deployment," said Saad Nadeem, PhD, Associate Attending Computer Scientist at MSK.

"This open source IMS initiative is an important first step, providing opportunities for companies/institutions to develop, deploy, validate, monitor, and disseminate AI solutions with standardized workflows. Building on MSK's longstanding commitment and leadership in digital pathology, we look forward to working with our IMS Consortium partners to democratize access to digital pathology worldwide."